News | October 26, 2012

Biotronik Launches Implantable Arrhythmia Monitor

ClearSense Technology with unique three-vector design offers superior detection of arrhythmias and efficient implantation

Biotroniks BioMonitor EP Lab Implantable Cardiac Monitors

October 26, 2012 — Biotronik began its European market release of BioMonitor, an implantable cardiac device designed for accurate and reliable monitoring and management of patients with atrial fibrillation (AF) or unexplained syncope.

BioMonitor is a subcutaneous implantable leadless cardiac monitor for the long-term continuous remote monitoring of patients with arrhythmias such as AF, bradycardia, sudden rate drop, asystole and tachycardia.

As sensitivity and specificity are essential in the detection of arrhythmias such as AF, Biotronik has developed ClearSense Technology with a unique three-vector signal detection that produces highly precise and reliable arrhythmia monitoring.

The ClearSense Technology records three ECG channels converting them to one high quality ECG input signal to clearly distinguish on a beat-to-beat basis between a genuine signal and other artifacts such as myopotentials due to body muscle contractions. This innovative technology allows for optimal arrhythmia detection independent of the device’s implant orientation within the body and provides a longevity of 6.4 years.

BioMonitor is equipped with Biotronik’s home monitoring system, which provides daily remote data transfer without patient interaction — leading to high patient compliance. Its traffic light system streamlines monitoring by highlighting the most relevant information and providing accurate data for physicians to monitor and manage their patients effectively.

“Only long-term continuous monitoring with reliable arrhythmia detection offers the type of vital information necessary for physicians to make the right therapy decisions when managing patients with AF or unexplained syncope,” commented Professor Gerhard Hindricks, director of the department of electrophysiology at the Leipzig University Heart Center in Germany.

Hindricks together with professor Wilhelm Haverkamp (deputy of the department of cardiology at Charité Campus Virchow, Humboldt University Berlin) and professor Dietmar Bänsch (director of cardiology department and rhythmology at the Rostock University Hospital) are the world’s first physicians to implant the BioMonitor and take advantage of this new approach for monitoring AF in their patients.

“Effective management of AF and unexplained syncope starts with effective monitoring,” said Haverkamp. “BioMonitor, with its ClearSense technology, and Biotronik Home Monitoring offer the optimal combination of reliability and efficiency.”

The BioMonitor device marks a new product category in Biotronik’s device portfolio of pacemakers, implantable cardioverter-defibrillators and cardiac resynchronization therapy systems.

“BioMonitor supports physicians in every step of arrhythmia management, from diagnosis via monitoring to individualized therapy offering high quality solutions that benefit both physicians and patients,” explained Bänsch.

Sites involved in the first implantations of the BioMonitor:

  • Germany

Prof. Gerhard Hindricks, Leipzig University Heart Center
Prof. Wilhelm Haverkamp, Charité Campus Virchow,Humboldt University Berlin
Prof. Dietmar Bänsch, RostockUniversityHospital
Prof. Dietrich Andresen, Vivantes Klinikum Am Urban/Im Friedrichshain, Berlin
Dr. Dieter Bimmel, St-Marien-Hospital, Bonn

  • Italy

Dr. Gaetano Senatore, Ospedale Civile di Cirie

  • Spain

Dr. Jesús Rodríguez García, University Hospital Doce de Octubre, Madrid

  • Switzerland

Dr. David Hürlimann, University Hospital of Zurich
Dr. Jan Steffel, University Hospital of Zurich

  • France

Dr. Arnaud Lazarus, Clinique Ambroise Paré, Paris

  • Denmark

Dr. Jens Brock Johansen, Odense University Hospital

 

For more information: www.biotronik.com

Related Content

Fysicon Receives FDA Approval for QMAPP Hemodynamic Monitoring System
Technology | Hemodynamic Monitoring Systems| September 18, 2017
Fysicon announced that it has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its...
Technavio Projects 9 Percent Global Growth for Electrophysiology Therapeutic Devices

Image courtesy of Technavio

News | EP Lab| September 11, 2017
September 11, 2017 — According to the latest market study released by Technavio, the global...
EMANATE Trial Shows Apixaban Lowers stroke in AF Patients Undergoing Cardioversion.
News | Atrial Fibrillation| September 01, 2017
September 1, 2017 — Apixaban lowers the risk of stroke compared to warfarin in anticoagulation-naïve patients with at
CASTLE-AF Study shows Catheter Ablation of Atrial Fibrillation is First-Line Treatment for Heart Failure Patients. Biotronic Ilivia 7 ICD.

The CASTLE-AF Study shows catheter alation of AF can be used effectively to treat heart failure in patients with an implanted ICD.

News | Atrial Fibrillation| September 01, 2017
September 1, 2017 — Final results from the CASTLE-AF study show a 38 percent reduction in the composite of all-cause
Abbott. St. Jude Medical has updated its firmware to address cybersecurity issues with its Allure Quadra MP and other EP devices

Abbott. St. Jude Medical has updated its firmware to address cybersecurity issues with its Allure Quadra MP and other EP devices.

Feature | EP Lab| August 29, 2017 | Dave Fornell
August 29, 2017 — The U.S.
Biotronik Announces U.S. Launch of Edora HF-T QP CRT Pacemaker
Technology | Cardiac Resynchronization Therapy Devices (CRT)| August 21, 2017
Biotronik announced U.S. Food and Drug Administration (FDA) approval and commercial availability of Edora HF-T QP, an...
The FDA is concerned about cybersecurity of ICDs and cyber security of other medical devices.
Feature | Cybersecurity| August 16, 2017 | Dave Fornell
There is growing concern among patients and regulators that medical devices, especially implantable electrophysiology
Three New Atrial Fibrillation Studies to Feature HeartLight Endoscopic Ablation System
News | Ablation Systems| August 07, 2017
CardioFocus Inc. announced that its HeartLight Endoscopic Ablation System is being featured in three new major clinical...
Merge Hemo cath lab hemodynamics monitoring system.

Hemodynamic data shown on screens from the Merge Hemo recording system. It is among the newer generation hemodynamic systems for cath labs that are more user friendly and have technologies to speed workflow.

Feature | Hemodynamic Monitoring Systems| August 03, 2017 | Dave Fornell
The current generation of...
Overlay Init